AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The company will start its confirmatory bexobrutideg study in June.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
Optimum-02 virtually replicates phase 1, and a filing will follow.
The group impresses in ovarian and endometrial cancers.
After setbacks, cema-cel might have a path to approval in lymphoma.
